Search for: "AMGEN INC." Results 1 - 20 of 704
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Federal Circuit Affirms Patent Rejection for Lack of Enablement in In re Pen
14 Jun 2024, 11:25 am by Dennis Crouch
”  Citing Amgen Inc. v. [read post]
Patently-O - https://patentlyo.com
Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944)
10 Jun 2024, 12:43 am by Rose Hughes
The Federal Circuit granted the motion to remand (In re Xencor Inc., No. 23-2048 (Fed. [read post]
IPKat - http://ipkitten.blogspot.com/
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
Well Done - https://www.morganlewis.com/blogs/welldone
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
Tech & Sourcing @ Morgan Lewis - https://www.morganlewis.com/blogs/sourcingatmorganlewis
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
As Prescribed - https://www.morganlewis.com/blogs/asprescribed
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
ML BeneBits - https://www.morganlewis.com/blogs/mlbenebits
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
Up & Atom - https://www.morganlewis.com/blogs/upandatom
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
Power & Pipes - https://www.morganlewis.com/blogs/powerandpipes
USPTO ARP Panel Restores MPF Sanity, but Still Rejects Xencor’s Claims
17 May 2024, 9:37 pm by Dennis Crouch
Although not directly related, the Supreme Court’s May 18, 2023 decision in Amgen v. [read post]
Patently-O - https://patentlyo.com
Discerning Signal from Noise: Navigating the Flood of AI-Generated Prior Art
30 Apr 2024, 7:30 am by Dennis Crouch
Amgen Inc. v. [read post]
Patently-O - https://patentlyo.com
Without Undue Experimentation vs Without Any Experiments
26 Apr 2024, 12:41 pm by Dennis Crouch
by Dennis Crouch I was rereading the Supreme Court’s recent enablement decision of Amgen Inc. v. [read post]
Patently-O - https://patentlyo.com
What is Next for Enablement and Written Description of Antibody Claims?
23 Apr 2024, 10:28 am by Dennis Crouch
See, Amgen Inc. v. [read post]
Patently-O - https://patentlyo.com
Federal Circuit Debates Scope of 271(e)(1) Safe Harbor and the Meaning of “Solely”
27 Mar 2024, 4:46 pm by Dennis Crouch
Amgen Inc. v. [read post]
Patently-O - https://patentlyo.com
Federal Circuit Applies Safe Harbor to Imported Medical Device Samples
27 Mar 2024, 10:56 am by Matt Kurnick
The 2019 decision Amgen Inc. v. [read post]
PharmaPatents - https://www.foley.com/en/insights/blogs/pharmapatents
What Do We Do with Presumptions in Antitrust?
25 Jan 2024, 6:32 am by Daniel J. Gilman
  The FTC also touted its settlement of the Amgen/Horizon matter (here and here) although, as I explained in December, the core of the consent order—reached on the eve of trial—had been proposed by Amgen all along. [read post]
Truth on the Market - http://truthonthemarket.com/
Vanda Seeks Supreme Court Review on Lower Standard for Obviousness
23 Jan 2024, 3:43 am by Dennis Crouch
Vanda Pharmaceuticals Inc., v. [read post]
Patently-O - https://patentlyo.com
Wachtell Lipton Discusses U.S. M&A Antitrust Enforcement for  2023 and the Year Ahead
21 Jan 2024, 9:01 pm by renholding
  In Seven & i Holdings Co., Ltd. and 7-Eleven, Inc. [read post]
The CLS Blue Sky Blog - https://clsbluesky.law.columbia.edu/
USPTO Issues “Reasonable” Guidance on Enablement Under Amgen v. Sanofi
18 Jan 2024, 5:14 pm by bklemm@foley.com
Share on LinkedInShare on TwitterShare by EmailShare Back to top The USPTO has issued “Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. [read post]
PharmaPatents - https://www.foley.com/en/insights/blogs/pharmapatents
USPTO Guidelines: Amgen is a Nothingburger
11 Jan 2024, 12:59 pm by Dennis Crouch
Genentech, Inc., 81 F.4th 1362 (Fed. [read post]
Patently-O - https://patentlyo.com
Federal Circuit Affirms Invalidity of Genus Claims to Stevia Production Method Lacking Written Description and Narrower Claims as Combining Natural Phenomena with an Abstract Idea
4 Jan 2024, 9:42 am by Dennis Crouch
SweeGen, Inc., No. 22-1946 (Fed. [read post]
Patently-O - https://patentlyo.com